Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

TSVT

2seventy bio (TSVT)

2seventy bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TSVT
DateTimeSourceHeadlineSymbolCompany
06/06/202409:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
06/06/202409:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
23/05/202421:00Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
17/05/202408:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
10/05/202406:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSVT2seventy bio Inc
08/05/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
08/05/202421:00Business Wire2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
03/05/202421:00Business Wire2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:TSVT2seventy bio Inc
06/04/202400:05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNASDAQ:TSVT2seventy bio Inc
01/04/202422:30Business Wire2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronNASDAQ:TSVT2seventy bio Inc
21/03/202408:04Business Wire2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsNASDAQ:TSVT2seventy bio Inc
16/03/202409:27Business WireFDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyNASDAQ:TSVT2seventy bio Inc
08/03/202408:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TSVT2seventy bio Inc
05/03/202423:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
05/03/202423:00Business Wire2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
01/03/202423:00Business Wire2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
06/02/202408:05Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202423:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
05/02/202422:59Business WireBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyNASDAQ:TSVT2seventy bio Inc
03/02/202408:54Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TSVT2seventy bio Inc
31/01/202401:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:TSVT2seventy bio Inc
30/01/202423:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
30/01/202423:01Business Wire2seventy bio Announces New Strategic Path ForwardNASDAQ:TSVT2seventy bio Inc
06/01/202408:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSVT2seventy bio Inc
12/12/202323:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
12/12/202311:30Business WireAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3NASDAQ:TSVT2seventy bio Inc
11/12/202323:00Business Wire2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)NASDAQ:TSVT2seventy bio Inc
07/12/202306:00Business Wire2seventy bio Reiterates Commitment to Maximizing Shareholder ValueNASDAQ:TSVT2seventy bio Inc
01/12/202322:49Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
01/12/202322:46Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
 Showing the most relevant articles for your search:NASDAQ:TSVT

Your Recent History

Delayed Upgrade Clock